List-I | List-II | ||
(A) | Gene therapy | (I) | Separation of DNA fragments |
(B) | RNA interference | (II) | Diagnostic test for AIDS |
(C) | ELISA | (III) | Cellular defense |
(D) | Gel Electrophoresis | (IV) | Allows correction of a gene defect |
Options: | (A) | (B) | (C) | (D) |
1. | IV | I | II | III |
2. | IV | II | III | I |
3. | IV | III | II | I |
4. | IV | III | I | II |
1. | Genetically engineered lymphocytes are not immortal cells. |
2. | Retroviral vector is introduced into these lymphocytes. |
3. | Gene isolated from marrow cells producing ADA is introduced into cells at embryonic stages |
4. | Lymphocytes from patient's blood are grown in culture, outside the body. |
When gene targeting involving gene amplification is attempted in an individual's tissue to treat disease, it is known as:
1. Molecular diagnosis
2. Safety testing
3. Biopiracy
4. Gene therapy
The Adenosine deaminase deficiency results into:
1. | Digestive disorder | 2. | Addison's disease |
3. | Dysfunction of Immune system | 4. | Parkinson's disease |
Which kind of therapy was given in 1990 to a four-year-old girl with Adenosine Deaminase (ADA) deficiency?
1. Gene therapy
2. Chemotherapy
3. Immunotherapy
4. Radiation therapy
The genetic defect-Adenosine Deaminase (ADA) deficiency may be cured permanently by:
1. | periodic infusion of genetically engineered lymphocytes having functional ADA cDNA |
2. | administering adenosine deaminase activators |
3. | introducing bone marrow cells producing ADA into cells at early embryonic stages |
4. | invitro cell culture therapy |